Proactive Investors - Run By Investors For Investors

Paradigm Biopharmaceuticals gets a speeding ticket for 18% price increase

Over the past year, shares have come from 29 cents to be trading at around $1.90.
asx electronic board
Earlier this month, director Christopher Fullerton purchased 100,000 shares

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has responded to a Price Query from the ASX regarding its run from its $1.605 close Tuesday to $1.90 yesterday, a gain of 18.3%.

The company responded to the ASX saying it was not aware of any relevant information not released to the market.

Paradigm went on to say that it believes a number of factors provide a possible explanation for the recent trading.

READ: Paradigm Biopharmaceuticals director shows confidence with on-market share purchase

Paradigm wrote: “As previously reported, Paradigm Biopharmaceuticals Ltd (ASX: PAR) intends to report on the secondary endpoints to its Phase 2b osteoarthritis randomised, double-blind,  placebo-controlled, multicentred clinical trial (the Phase 2b OA Clinical Trial) in Q1/Q2 CY2019.

“On the 18th and 20th December 2018, Paradigm reported the top-line results to the Phase 2b OA Clinical Trial. The top-line results were positive with the primary end-point being achieved.

READ: Paradigm Biopharmaceuticals moving towards phase 2/3 MPS clinical trial

“At the same time it was disclosed that Paradigm would report the outcome of the Phase 2b OA Clinical Trial secondary endpoints in Q1/Q2 CY2019. As disclosed in the clinical trial protocol, the secondary endpoints that will be reported are:

1. Mean change in KOOS pain score from baseline to day 165 – which measures durability of effect for the drug up to approximately 6 months;
2. Mean percentage change in KOOS Activity of Daily Living (ADL) from baseline to day 165 – which measures daily activities such as walking, going up and down stairs etc;
3. Proportion of subjects with >50% reduction in KOOS pain from baseline to day 165 – which indicates the proportion of subjects receiving a very strong (>50%) clinically meaningful benefit;
4. Change in bone marrow lesion (BML) volume between pre-treatment MRI and posttreatment MRI at day 53 – is an objective and indisputable measure and indicates if the drug is working to slow the progression of the disease. An increasing BML indicates progression (worsening) of the disease whilst a decreasing BML indicates regression (improvement) of the disease.

“The complete and final data set has not yet been received by the Company and there is nothing new to report. However, the Company will report on the Phase 2b secondary endpoints when the final data is ready for disclosure to the market.

READ: Paradigm Biopharmaceuticals to court partners and licensees for OA drug commercialisation

“Due to the comprehensive nature of this secondary endpoint data it is expected to be of significant interest to both the investment community and the pharmaceutical industry, hence the increasing attention the company is receiving in the lead up to the release of these results.

“In addition, we also note technical analysis supports strong positive trading momentum, potentially further adding to the current interest in the company.”

View full PAR profile View Profile

Paradigm Biopharmaceuticals Ltd Timeline

Related Articles

scientists in a lab
January 30 2019
The technology first drew the attention of ChemioCare CEO Pedro Lichtinger years ago while he oversaw Pfizer's global primary care business
1550850611_CancerHeadline.jpg
February 22 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”
human kidneys
May 06 2019
The Danish company is seeking FDA approval of the test for use in both adults and children
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use